Pharmicell Co., Ltd. (005690.KS)
KRW 9440.0
(3.85%)
KRW 9440.0
(3.85%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 20.87 Billion KRW | -8.7% |
| 2022 | 22.86 Billion KRW | 35.34% |
| 2021 | 16.89 Billion KRW | 166.51% |
| 2020 | 6.33 Billion KRW | -22.96% |
| 2019 | 8.22 Billion KRW | 53.03% |
| 2018 | 5.37 Billion KRW | -1.17% |
| 2017 | 5.43 Billion KRW | 39.43% |
| 2016 | 3.9 Billion KRW | 39.74% |
| 2015 | 2.79 Billion KRW | 7.87% |
| 2014 | 2.58 Billion KRW | -43.9% |
| 2013 | 4.61 Billion KRW | -8.19% |
| 2012 | 5.02 Billion KRW | 107.34% |
| 2011 | 2.42 Billion KRW | 106.17% |
| 2010 | 1.17 Billion KRW | 183.06% |
| 2009 | 415.32 Million KRW | -75.58% |
| 2008 | 1.7 Billion KRW | -63.87% |
| 2007 | 4.7 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 20.18 Billion KRW | -3.8% |
| 2024 Q1 | 20.98 Billion KRW | 0.53% |
| 2023 Q1 | 23.84 Billion KRW | 4.29% |
| 2023 Q4 | 20.87 Billion KRW | -4.24% |
| 2023 FY | 20.87 Billion KRW | -8.7% |
| 2023 Q2 | 21.79 Billion KRW | -8.59% |
| 2023 Q3 | 21.79 Billion KRW | 0.01% |
| 2022 Q2 | 15.73 Billion KRW | 2.59% |
| 2022 FY | 22.86 Billion KRW | 35.34% |
| 2022 Q4 | 22.86 Billion KRW | 34.8% |
| 2022 Q3 | 16.95 Billion KRW | 7.75% |
| 2022 Q1 | 15.34 Billion KRW | -9.17% |
| 2021 Q1 | 7.79 Billion KRW | 23.02% |
| 2021 Q4 | 16.89 Billion KRW | 70.53% |
| 2021 Q2 | 7.92 Billion KRW | 1.68% |
| 2021 Q3 | 9.9 Billion KRW | 24.94% |
| 2021 FY | 16.89 Billion KRW | 166.51% |
| 2020 FY | 6.33 Billion KRW | -22.96% |
| 2020 Q1 | 6.31 Billion KRW | -23.22% |
| 2020 Q3 | 5.45 Billion KRW | -7.31% |
| 2020 Q4 | 6.33 Billion KRW | 16.09% |
| 2020 Q2 | 5.89 Billion KRW | -6.74% |
| 2019 Q4 | 8.22 Billion KRW | -12.65% |
| 2019 FY | 8.22 Billion KRW | 53.03% |
| 2019 Q3 | 9.41 Billion KRW | 20.65% |
| 2019 Q2 | 7.8 Billion KRW | 33.46% |
| 2019 Q1 | 5.84 Billion KRW | 8.81% |
| 2018 Q4 | 5.37 Billion KRW | -11.17% |
| 2018 Q2 | 6.37 Billion KRW | 8.39% |
| 2018 FY | 5.37 Billion KRW | -1.17% |
| 2018 Q1 | 5.88 Billion KRW | 8.14% |
| 2018 Q3 | 6.05 Billion KRW | -5.08% |
| 2017 Q1 | 5.27 Billion KRW | 35.16% |
| 2017 Q4 | 5.43 Billion KRW | -12.51% |
| 2017 FY | 5.43 Billion KRW | 39.43% |
| 2017 Q3 | 6.21 Billion KRW | 31.81% |
| 2017 Q2 | 4.71 Billion KRW | -10.55% |
| 2016 Q2 | 4.2 Billion KRW | 22.93% |
| 2016 Q4 | 3.9 Billion KRW | -10.49% |
| 2016 FY | 3.9 Billion KRW | 39.74% |
| 2016 Q3 | 4.35 Billion KRW | 3.62% |
| 2016 Q1 | 3.42 Billion KRW | 22.57% |
| 2015 Q2 | 3.13 Billion KRW | -2.75% |
| 2015 FY | 2.79 Billion KRW | 7.87% |
| 2015 Q4 | 2.79 Billion KRW | -7.32% |
| 2015 Q3 | 3.01 Billion KRW | -3.89% |
| 2015 Q1 | 3.22 Billion KRW | 24.52% |
| 2014 FY | 2.58 Billion KRW | -43.9% |
| 2014 Q3 | 3.29 Billion KRW | 3.06% |
| 2014 Q2 | 3.2 Billion KRW | -11.77% |
| 2014 Q1 | 3.62 Billion KRW | -21.38% |
| 2014 Q4 | 2.58 Billion KRW | -21.53% |
| 2013 Q3 | 4.07 Billion KRW | -1.38% |
| 2013 Q4 | 4.61 Billion KRW | 13.33% |
| 2013 Q2 | 4.12 Billion KRW | 0.04% |
| 2013 Q1 | 4.12 Billion KRW | -17.89% |
| 2013 FY | 4.61 Billion KRW | -8.19% |
| 2012 FY | 5.02 Billion KRW | 107.34% |
| 2012 Q4 | 5.02 Billion KRW | 0.0% |
| 2012 Q1 | 2.52 Billion KRW | 0.0% |
| 2011 Q3 | 3.32 Billion KRW | 37.91% |
| 2011 Q2 | 2.41 Billion KRW | 4.27% |
| 2011 Q1 | 2.31 Billion KRW | 96.7% |
| 2011 FY | 2.42 Billion KRW | 106.17% |
| 2010 Q1 | 142.96 Million KRW | -65.58% |
| 2010 Q4 | 1.17 Billion KRW | 241.91% |
| 2010 FY | 1.17 Billion KRW | 183.06% |
| 2010 Q2 | 166.84 Million KRW | 16.7% |
| 2010 Q3 | 343.83 Million KRW | 106.08% |
| 2009 Q3 | 386.41 Million KRW | -80.73% |
| 2009 Q2 | 2 Billion KRW | 51.01% |
| 2009 Q1 | 1.32 Billion KRW | -21.9% |
| 2009 FY | 415.32 Million KRW | -75.58% |
| 2009 Q4 | 415.32 Million KRW | 7.48% |
| 2008 Q1 | 4.02 Billion KRW | -14.49% |
| 2008 Q4 | 1.7 Billion KRW | -30.24% |
| 2008 FY | 1.7 Billion KRW | -63.87% |
| 2008 Q2 | 3.31 Billion KRW | -17.72% |
| 2008 Q3 | 2.43 Billion KRW | -26.38% |
| 2007 FY | 4.7 Billion KRW | 0.0% |
| 2007 Q4 | 4.7 Billion KRW | 0.52% |
| 2007 Q3 | 4.68 Billion KRW | 27.83% |
| 2007 Q2 | 3.66 Billion KRW | 7.54% |
| 2007 Q1 | 3.4 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ORIENT BIO Inc. | 3.65 Billion KRW | -471.156% |
| Green Cross Holdings Corporation | 579.72 Billion KRW | 96.4% |
| Green Cross Holdings Corporation | 516.24 Billion KRW | 95.957% |
| Green Cross Corporation | 516.24 Billion KRW | 95.957% |
| GeneOne Life Science, Inc. | 14.89 Billion KRW | -40.112% |
| Celltrion, Inc. | 3041.45 Billion KRW | 99.314% |
| Samsung Biologics Co.,Ltd. | 2641.36 Billion KRW | 99.21% |
| SK bioscience Co.,Ltd. | 80.64 Billion KRW | 74.12% |
| SK Biopharmaceuticals Co., Ltd. | 102.52 Billion KRW | 79.642% |
| Prestige BioPharma Limited | 18.1 Billion KRW | -15.298% |